Emerging trends in hepatocellular carcinoma: Focus on diagnosis and therapeutics

Avegail Flores, Jorge A. Marrero

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is one of the most common tumors worldwide and one of the deadliest. Patients with chronic liver disease are at the highest risk for developing this tumor. This link provides an opportunity for developing preventive strategies and surveillance that aims at early detection of this tumor and possibly improving outcomes. In this review, we will discuss the latest developments in surveillance strategies, diagnosis, and treatment of this tumor. HCC is the sixth most common cancer in the world, with 782,000 new cases occurring in 2012 worldwide. In 2012, there were 746,000 deaths from liver cancer.1 HCC is the third most fatal cancer in the world.2 The distribution of HCC, which varies geographically, is related to the prevalence of hepatotropic virus. The burden of the disease is the highest in Eastern Asia, sub-Saharan Africa, and Melanesia where hepatitis B (HBV) infection is endemic. Meanwhile, in Japan, United States, and Europe, hepatitis C (HCV) infection is prevalent, and subsequently, is the major risk factor for acquiring HCC in these regions.1,3 It is estimated that the incidence of HCC in Europe and United States will peak at 2020-there will be 78,000 new HCC cases in Europe and 27,000 in the United States-and decline thereafter.1 Indeed, in Japan, the incidence of HCC had already plateaued and started to slowly fall.4 Cirrhosis is the most important risk factor for HCC regardless of etiology and may be caused by chronic viral hepatitis (mainly HBV and HCV), alcoholic liver disease, autoimmune disease, Stage 4 primary biliary cirrhosis, and metabolic diseases such as hereditary hemochromatosis, alpha-1 antitrypsin deficiency, and non-alcoholic fatty liver disease. In the Western hemi-sphere, HCC occurs in a background of cirrhosis in 90% of the cases.5 Before concentrating on diagnosis and therapeutics, it is important to discuss surveillance for this tumor.

Original languageEnglish (US)
Pages (from-to)71-76
Number of pages6
JournalClinical Medicine Insights: Oncology
Volume8
DOIs
StatePublished - May 19 2014

Fingerprint

Hepatocellular Carcinoma
Neoplasms
Therapeutics
Japan
Fibrosis
Melanesia
alpha 1-Antitrypsin Deficiency
Alcoholic Liver Diseases
Hemochromatosis
Far East
Biliary Liver Cirrhosis
Africa South of the Sahara
Metabolic Diseases
Incidence
Chronic Hepatitis
Hepatitis C
Infection
Hepatitis B
Autoimmune Diseases
Liver Diseases

Keywords

  • Alpha-fetoprotein (AFP)
  • Dynamic imaging
  • Hepatocellular carcinoma (HCC)
  • Liver transplantation
  • Molecular targets
  • Radiofrequency ablation (RFA)
  • Sorafenib
  • Trans-arterial chemoembolization (TACE)
  • Ultrasound
  • Yttrium-90 (Y-90) radioembolization

ASJC Scopus subject areas

  • Oncology

Cite this

Emerging trends in hepatocellular carcinoma : Focus on diagnosis and therapeutics. / Flores, Avegail; Marrero, Jorge A.

In: Clinical Medicine Insights: Oncology, Vol. 8, 19.05.2014, p. 71-76.

Research output: Contribution to journalArticle

@article{1b8bbbfb2e464993a4cf26335bc295ae,
title = "Emerging trends in hepatocellular carcinoma: Focus on diagnosis and therapeutics",
abstract = "Hepatocellular carcinoma (HCC) is one of the most common tumors worldwide and one of the deadliest. Patients with chronic liver disease are at the highest risk for developing this tumor. This link provides an opportunity for developing preventive strategies and surveillance that aims at early detection of this tumor and possibly improving outcomes. In this review, we will discuss the latest developments in surveillance strategies, diagnosis, and treatment of this tumor. HCC is the sixth most common cancer in the world, with 782,000 new cases occurring in 2012 worldwide. In 2012, there were 746,000 deaths from liver cancer.1 HCC is the third most fatal cancer in the world.2 The distribution of HCC, which varies geographically, is related to the prevalence of hepatotropic virus. The burden of the disease is the highest in Eastern Asia, sub-Saharan Africa, and Melanesia where hepatitis B (HBV) infection is endemic. Meanwhile, in Japan, United States, and Europe, hepatitis C (HCV) infection is prevalent, and subsequently, is the major risk factor for acquiring HCC in these regions.1,3 It is estimated that the incidence of HCC in Europe and United States will peak at 2020-there will be 78,000 new HCC cases in Europe and 27,000 in the United States-and decline thereafter.1 Indeed, in Japan, the incidence of HCC had already plateaued and started to slowly fall.4 Cirrhosis is the most important risk factor for HCC regardless of etiology and may be caused by chronic viral hepatitis (mainly HBV and HCV), alcoholic liver disease, autoimmune disease, Stage 4 primary biliary cirrhosis, and metabolic diseases such as hereditary hemochromatosis, alpha-1 antitrypsin deficiency, and non-alcoholic fatty liver disease. In the Western hemi-sphere, HCC occurs in a background of cirrhosis in 90{\%} of the cases.5 Before concentrating on diagnosis and therapeutics, it is important to discuss surveillance for this tumor.",
keywords = "Alpha-fetoprotein (AFP), Dynamic imaging, Hepatocellular carcinoma (HCC), Liver transplantation, Molecular targets, Radiofrequency ablation (RFA), Sorafenib, Trans-arterial chemoembolization (TACE), Ultrasound, Yttrium-90 (Y-90) radioembolization",
author = "Avegail Flores and Marrero, {Jorge A.}",
year = "2014",
month = "5",
day = "19",
doi = "10.4137/CMO.S9926",
language = "English (US)",
volume = "8",
pages = "71--76",
journal = "Clinical Medicine Insights: Oncology",
issn = "1179-5549",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Emerging trends in hepatocellular carcinoma

T2 - Focus on diagnosis and therapeutics

AU - Flores, Avegail

AU - Marrero, Jorge A.

PY - 2014/5/19

Y1 - 2014/5/19

N2 - Hepatocellular carcinoma (HCC) is one of the most common tumors worldwide and one of the deadliest. Patients with chronic liver disease are at the highest risk for developing this tumor. This link provides an opportunity for developing preventive strategies and surveillance that aims at early detection of this tumor and possibly improving outcomes. In this review, we will discuss the latest developments in surveillance strategies, diagnosis, and treatment of this tumor. HCC is the sixth most common cancer in the world, with 782,000 new cases occurring in 2012 worldwide. In 2012, there were 746,000 deaths from liver cancer.1 HCC is the third most fatal cancer in the world.2 The distribution of HCC, which varies geographically, is related to the prevalence of hepatotropic virus. The burden of the disease is the highest in Eastern Asia, sub-Saharan Africa, and Melanesia where hepatitis B (HBV) infection is endemic. Meanwhile, in Japan, United States, and Europe, hepatitis C (HCV) infection is prevalent, and subsequently, is the major risk factor for acquiring HCC in these regions.1,3 It is estimated that the incidence of HCC in Europe and United States will peak at 2020-there will be 78,000 new HCC cases in Europe and 27,000 in the United States-and decline thereafter.1 Indeed, in Japan, the incidence of HCC had already plateaued and started to slowly fall.4 Cirrhosis is the most important risk factor for HCC regardless of etiology and may be caused by chronic viral hepatitis (mainly HBV and HCV), alcoholic liver disease, autoimmune disease, Stage 4 primary biliary cirrhosis, and metabolic diseases such as hereditary hemochromatosis, alpha-1 antitrypsin deficiency, and non-alcoholic fatty liver disease. In the Western hemi-sphere, HCC occurs in a background of cirrhosis in 90% of the cases.5 Before concentrating on diagnosis and therapeutics, it is important to discuss surveillance for this tumor.

AB - Hepatocellular carcinoma (HCC) is one of the most common tumors worldwide and one of the deadliest. Patients with chronic liver disease are at the highest risk for developing this tumor. This link provides an opportunity for developing preventive strategies and surveillance that aims at early detection of this tumor and possibly improving outcomes. In this review, we will discuss the latest developments in surveillance strategies, diagnosis, and treatment of this tumor. HCC is the sixth most common cancer in the world, with 782,000 new cases occurring in 2012 worldwide. In 2012, there were 746,000 deaths from liver cancer.1 HCC is the third most fatal cancer in the world.2 The distribution of HCC, which varies geographically, is related to the prevalence of hepatotropic virus. The burden of the disease is the highest in Eastern Asia, sub-Saharan Africa, and Melanesia where hepatitis B (HBV) infection is endemic. Meanwhile, in Japan, United States, and Europe, hepatitis C (HCV) infection is prevalent, and subsequently, is the major risk factor for acquiring HCC in these regions.1,3 It is estimated that the incidence of HCC in Europe and United States will peak at 2020-there will be 78,000 new HCC cases in Europe and 27,000 in the United States-and decline thereafter.1 Indeed, in Japan, the incidence of HCC had already plateaued and started to slowly fall.4 Cirrhosis is the most important risk factor for HCC regardless of etiology and may be caused by chronic viral hepatitis (mainly HBV and HCV), alcoholic liver disease, autoimmune disease, Stage 4 primary biliary cirrhosis, and metabolic diseases such as hereditary hemochromatosis, alpha-1 antitrypsin deficiency, and non-alcoholic fatty liver disease. In the Western hemi-sphere, HCC occurs in a background of cirrhosis in 90% of the cases.5 Before concentrating on diagnosis and therapeutics, it is important to discuss surveillance for this tumor.

KW - Alpha-fetoprotein (AFP)

KW - Dynamic imaging

KW - Hepatocellular carcinoma (HCC)

KW - Liver transplantation

KW - Molecular targets

KW - Radiofrequency ablation (RFA)

KW - Sorafenib

KW - Trans-arterial chemoembolization (TACE)

KW - Ultrasound

KW - Yttrium-90 (Y-90) radioembolization

UR - http://www.scopus.com/inward/record.url?scp=84901241878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901241878&partnerID=8YFLogxK

U2 - 10.4137/CMO.S9926

DO - 10.4137/CMO.S9926

M3 - Article

C2 - 24899827

AN - SCOPUS:84901241878

VL - 8

SP - 71

EP - 76

JO - Clinical Medicine Insights: Oncology

JF - Clinical Medicine Insights: Oncology

SN - 1179-5549

ER -